I. Gantz and T. Fong, The melanocortin system: Table 1., American Journal of Physiology - Endocrinology And Metabolism, vol.284, issue.3, pp.468-74, 2003.
DOI : 10.1152/ajpendo.00434.2002

D. Rossi and A. Zlotnik, The Biology of Chemokines and their Receptors, Annual Review of Immunology, vol.18, issue.1, pp.217-259, 2000.
DOI : 10.1146/annurev.immunol.18.1.217

R. Ames, H. Sarau, J. Chambers, R. Willette, N. Aiyar et al., Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14, Nature, vol.401, issue.6750, pp.282-288, 1999.
DOI : 10.1038/45809

H. Vaudry, D. Rego, J. , L. Mevel, J. Chatenet et al., Urotensin II, from fish to human, Annals of the New York Academy of Sciences, vol.117, issue.1, pp.53-66, 2010.
DOI : 10.1111/j.1749-6632.2010.05514.x
URL : https://hal.archives-ouvertes.fr/pasteur-00819531

T. Sugo and M. Mori, Another ligand fishing for G protein-coupled receptor 14, Peptides, vol.29, issue.5, pp.809-821, 2008.
DOI : 10.1016/j.peptides.2007.06.005

J. Leprince, D. Chatenet, C. Dubessy, A. Fournier, B. Pfeiffer et al., Structure???activity relationships of urotensin II and URP, Peptides, vol.29, issue.5, pp.658-73, 2008.
DOI : 10.1016/j.peptides.2007.08.014

M. Jarry, M. Diallo, C. Lecointre, L. Desrues, T. Tokay et al., The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation, Biochemical Journal, vol.451, issue.1, pp.113-137, 2010.
DOI : 10.1016/j.atherosclerosis.2005.10.044
URL : https://hal.archives-ouvertes.fr/hal-00479207

H. Prosser, M. Forster, A. Richards, and C. Pemberton, Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury, Peptides, vol.29, issue.5, pp.770-777, 2008.
DOI : 10.1016/j.peptides.2007.08.013

B. Maryanoff and W. Kinney, Urotensin-II Receptor Modulators as Potential Drugs, Journal of Medicinal Chemistry, vol.53, issue.7, pp.2695-708, 2010.
DOI : 10.1021/jm901294u

B. Ross, K. Mckendy, and A. Giaid, Role of urotensin II in health and disease, AJP: Regulatory, Integrative and Comparative Physiology, vol.298, issue.5, pp.1156-72, 2010.
DOI : 10.1152/ajpregu.00706.2009

M. Malagon, M. Molina, M. Gahete, M. Duran-prado, A. Martinez-fuentes et al., Urotensin II and urotensin II-related peptide activate somatostatin receptor subtypes 2 and 5, Peptides, vol.29, issue.5, pp.711-731, 2008.
DOI : 10.1016/j.peptides.2007.12.015

W. Rossowski, B. Cheng, J. Taylor, R. Datta, and D. Coy, Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists, European Journal of Pharmacology, vol.438, issue.3, pp.159-70, 2002.
DOI : 10.1016/S0014-2999(02)01341-9

D. Ferone, M. Boschetti, E. Resmini, M. Giusti, V. Albanese et al., Neuroendocrine-Immune Interactions: The Role of Cortistatin/Somatostatin System, Annals of the New York Academy of Sciences, vol.18, issue.1, pp.129-173, 2006.
DOI : 10.1002/art.20184

A. Spier and L. De-lecea, Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions, Brain Research Reviews, vol.33, issue.2-3, pp.228-269, 2000.
DOI : 10.1016/S0165-0173(00)00031-X

H. Tostivint, L. Joly, I. Lihrmann, C. Parmentier, A. Lebon et al., Comparative genomics provides evidence for close evolutionary relationships between the urotensin II and somatostatin gene families, Proceedings of the National Academy of Sciences, vol.103, issue.7, pp.2237-2279, 2006.
DOI : 10.1073/pnas.0510700103

P. Grieco, A. Carotenuto, P. Campiglia, L. Marinelli, T. Lama et al., Urotensin-II Receptor Ligands. From Agonist to Antagonist Activity, Journal of Medicinal Chemistry, vol.48, issue.23, pp.7290-7297, 2005.
DOI : 10.1021/jm058043j

A. Lavecchia, S. Cosconati, and E. Novellino, Architecture of the Human Urotensin II Receptor:?? Comparison of the Binding Domains of Peptide and Non-Peptide Urotensin II Agonists, Journal of Medicinal Chemistry, vol.48, issue.7, pp.2480-92, 2005.
DOI : 10.1021/jm049110x

D. Chatenet, C. Dubessy, J. Leprince, C. Boularan, and L. Carlier, Structure???activity relationships and structural conformation of a novel urotensin II-related peptide, Peptides, vol.25, issue.10, pp.1819-1849, 2004.
DOI : 10.1016/j.peptides.2004.04.019

J. Erchegyi, R. Cescato, C. Grace, B. Waser, V. Piccand et al., ) Selective Analogues, Journal of Medicinal Chemistry, vol.52, issue.9, pp.2733-2779, 2009.
DOI : 10.1021/jm801314f

S. Bourgault, M. Letourneau, and A. Fournier, Development of photolabile caged analogs of endothelin-1, Peptides, vol.28, issue.5, pp.1074-82, 2007.
DOI : 10.1016/j.peptides.2007.02.013
URL : https://hal.archives-ouvertes.fr/pasteur-00819999

A. Brkovic, A. Hattenberger, E. Kostenis, T. Klabunde, S. Flohr et al., Functional and Binding Characterizations of Urotensin II-Related Peptides in Human and Rat Urotensin II-Receptor Assay, Journal of Pharmacology and Experimental Therapeutics, vol.306, issue.3, pp.1200-1209, 2003.
DOI : 10.1124/jpet.103.052415

N. Doan, T. Nguyen, M. Letourneau, K. Turcotte, A. Fournier et al., Biochemical and pharmacological characterization of nuclear urotensin-II binding sites in rat heart, British Journal of Pharmacology, vol.6, issue.1, 2011.
DOI : 10.1111/j.1476-5381.2011.01710.x
URL : https://hal.archives-ouvertes.fr/pasteur-00818552

H. Castel, M. Diallo, D. Chatenet, J. Leprince, L. Desrues et al., Biochemical and functional characterization of high-affinity urotensin???II receptors in rat cortical astrocytes, Journal of Neurochemistry, vol.22, issue.2, pp.582-95, 2006.
DOI : 10.1111/j.1471-4159.2006.04130.x

G. Gendron, G. Jr, F. Belanger, S. Gagnon, S. Regoli et al., Urotensin II-induced hypotensive responses in Wistar???Kyoto (Wky) and spontaneously hypertensive (Shr) rats, Peptides, vol.26, issue.8, pp.1468-74, 2005.
DOI : 10.1016/j.peptides.2005.03.012

D. Behm, N. Aiyar, A. Olzinski, J. Mcatee, M. Hilfiker et al., GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo, British Journal of Pharmacology, vol.285, issue.1, pp.207-235, 2010.
DOI : 10.1111/j.1476-5381.2010.00889.x

D. Behm, C. Herold, E. Ohlstein, S. Knight, D. Dhanak et al., Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist, British Journal of Pharmacology, vol.508, issue.4, pp.449-58, 2002.
DOI : 10.1038/sj.bjp.0704887

G. Vauquelin, I. Van-liefde, and P. Vanderheyden, Models and methods for studying insurmountable antagonism, Trends in Pharmacological Sciences, vol.23, issue.11, pp.514-522, 2002.
DOI : 10.1016/S0165-6147(02)02081-3

G. Hassan, F. Chouiali, T. Saito, F. Hu, S. Douglas et al., Effect of human urotensin-II infusion on hemodynamics and cardiac function, Canadian Journal of Physiology and Pharmacology, vol.81, issue.2, pp.125-133, 2003.
DOI : 10.1139/y03-004

T. Sugo, Y. Murakami, Y. Shimomura, M. Harada, M. Abe et al., Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain, Biochemical and Biophysical Research Communications, vol.310, issue.3, pp.860-868, 2003.
DOI : 10.1016/j.bbrc.2003.09.102

A. Gibson, P. Wallace, and H. Bern, Cardiovascular effects of urotensin II in anesthetized and pithed rats, General and Comparative Endocrinology, vol.64, issue.3, pp.435-444, 1986.
DOI : 10.1016/0016-6480(86)90080-8

T. Hirose, K. Takahashi, N. Mori, T. Nakayama, M. Kikuya et al., Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: Comparison with endothelin-1, Peptides, vol.30, issue.6, pp.1124-1133, 2009.
DOI : 10.1016/j.peptides.2009.02.009

S. Flohr, M. Kurz, E. Kostenis, A. Brkovich, A. Fournier et al., Identification of Nonpeptidic Urotensin II Receptor Antagonists by Virtual Screening Based on a Pharmacophore Model Derived from Structure???Activity Relationships and Nuclear Magnetic Resonance Studies on Urotensin II, Journal of Medicinal Chemistry, vol.45, issue.9, pp.1799-805, 2002.
DOI : 10.1021/jm0111043

M. Diallo, M. Jarry, L. Desrues, H. Castel, D. Chatenet et al., [Orn5]URP acts as a pure antagonist of urotensinergic receptors in rat cortical astrocytes, Peptides, vol.29, issue.5, pp.813-822, 2008.
DOI : 10.1016/j.peptides.2007.10.023

D. Behm, G. Stankus, C. Doe, R. Willette, H. Sarau et al., The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems, British Journal of Pharmacology, vol.508, issue.(Suppl. 2), pp.173-90, 2006.
DOI : 10.1038/sj.bjp.0706716

A. Kaumann and M. Frenken, A paradox: the 5-HT2-receptor antagonist ketanserin restores the 5-HT-induced contraction depressed by methysergide in large coronary arteries of calf, Naunyn-Schmiedeberg's Archives of Pharmacology, vol.218, issue.3, pp.295-300, 1985.
DOI : 10.1007/BF00515556

A. Abdelrahman and C. Pang, Involvement of the nitric oxide/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats, Life Sciences, vol.71, issue.7, pp.819-844, 2002.
DOI : 10.1016/S0024-3205(02)01743-5

S. Gao, Y. Oh, A. Shah, W. Park, M. Chung et al., Urotensin II receptor antagonist attenuates monocrotaline-induced cardiac hypertrophy in rats, AJP: Heart and Circulatory Physiology, vol.299, issue.6, pp.1782-1791, 2010.
DOI : 10.1152/ajpheart.00438.2010

G. Vauquelin, I. Van-liefde, B. Birzbier, and P. Vanderheyden, New insights in insurmountable antagonism, Fundamental and Clinical Pharmacology, vol.103, issue.4, pp.263-72, 2002.
DOI : 10.1016/S0002-9149(99)00728-6